Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03554642 · ClinicalTrials.gov registry record · Phase 3

Walkbot Robotic Training for Improvement in Gait

A Phase 3 study, sponsored by Burke Medical Research Institute.

Completed
Registry status
Phase 3
Development phase
30
Enrollment target

NCT03554642: Completed Phase 3 study, sponsored by Burke Medical Research Institute.

NCT03554642 is a Phase 3 study that has completed, run by Burke Medical Research Institute. The registered enrollment target is 30 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03554642, a Phase 3 study, has completed, sponsored by Burke Medical Research Institute.

COMPLETED
Registry status
Phase 3
Development phase
30 participants
Enrollment target

Study Summary

This clinical study will involve up to 30 ischemic stroke inpatients during their stay at Burke Rehabilitation Hospital. Participants will be randomized to receive 30 additional minutes of therapy every day, for a total of 2 weeks (14 days). One group will receive 30 minutes of standard physical therapy focused on pre-gait or gait training activities, while the experimental group will receive 30 minutes of Walkbot with Augmented Reality. Both groups will receive the same time in therapy aimed at gait training.

Primary Outcome

Lower extremity impairment measure

Interventions

  • BEHAVIORAL Physical Therapy
  • DEVICE Walkbot

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2016-09
Est. Completion 2019-12
Phase Phase 3
Burke Medical Research Institute

11 total trials

What the finished NCT03554642 record still lists

NCT03554642 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 2 interventions - of which Physical Therapy is the first listed.

NCT03554642 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03554642 about?

NCT03554642 is a clinical study titled "Walkbot Robotic Training for Improvement in Gait". This clinical study will involve up to 30 ischemic stroke inpatients during their stay at Burke Rehabilitation Hospital. Participants will be randomized to receive 30 additional minutes of therapy every day, for a total of 2 weeks (14 days). One group will receive 30 minutes of standard physical the...

What is the current status of trial NCT03554642?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2016-09. Estimated completion is 2019-12.

What interventions are being tested in trial NCT03554642?

The interventions under investigation include: Physical Therapy (BEHAVIORAL), Walkbot (DEVICE).

Who is sponsoring clinical trial NCT03554642?

This trial is sponsored by Burke Medical Research Institute, which has 11 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03554642's enrollment target sits among peer trials

30 1917th of 2000 higher than 68 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT03554642, the US trial registry maintained by the National Library of Medicine. NCT03554642 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.